批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2022/03/27 |
SUPPL-31(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/12/06 |
SUPPL-24(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/12/06 |
SUPPL-23(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2017/04/06 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/03/31 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/12/22 |
SUPPL-21(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2013/10/18 |
SUPPL-17(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2013/10/18 |
SUPPL-16(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2013/06/21 |
SUPPL-18(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/06/21 |
SUPPL-15(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/03/02 |
SUPPL-13(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/08/12 |
SUPPL-12(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/08/12 |
SUPPL-11(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2010/01/29 |
SUPPL-7(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2010/01/29 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/01/29 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2008/07/07 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/08/20 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/04/27 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/03/13 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:LAPATINIB DITOSYLATE 剂型/给药途径:TABLET;ORAL 规格:EQ 250MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022059 |
001 |
NDA |
TYKERB |
LAPATINIB DITOSYLATE |
TABLET;ORAL |
EQ 250MG BASE |
Prescription |
Yes |
Yes |
AB |
2007/03/13
|
NOVARTIS |
203007 |
001 |
ANDA |
LAPATINIB DITOSYLATE |
LAPATINIB DITOSYLATE |
TABLET;ORAL |
EQ 250MG BASE |
Prescription |
No |
No |
AB |
2020/09/29
|
NATCO PHARMA LTD |
217968 |
001 |
ANDA |
LAPATINIB DITOSYLATE |
LAPATINIB DITOSYLATE |
TABLET;ORAL |
EQ 250MG BASE |
Prescription |
No |
No |
AB |
2024/08/16
|
TEVA PHARMS USA INC |